AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29848776 — intervention group
Group type: COMPARATOR
Intervention: Absolute changes in NT-proBNP by 6 months
Number of subjects: 0
Study 27272083 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine cream 2%
Number of subjects: 231
Study 27272083 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 231
Study 25341903 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 88
Study 25341903 — intervention group
Group type: COMPARATOR
Intervention: Early fasting
Number of subjects: 88
Study 24071565 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg single dose)
Number of subjects: 0
Study 19997688 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice
Number of subjects: 107
Study 19997688 — intervention group
Group type: COMPARATOR
Intervention: Hospital practice
Number of subjects: 107
Study 18343652 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 IU, subcutaneously, once weekly) initiated within 7 days of the start of the first chemotherapy cycle
Number of subjects: 2
Study 18343652 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (epoetin alfa when Hb <= 10 g/dL)
Number of subjects: 2
Study 15633709 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient with amusia
Number of subjects: 1
Study 15633709 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 1
Study 12354473 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus sulfadoxine‐pyrimethamine
Number of subjects: 328
Study 12354473 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron alone
Number of subjects: 328
Study 12354473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine alone
Number of subjects: 328
Study 12354473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 10701699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 15 mg via short‐term i.v. infusion
Number of subjects: 36
Study 10701699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 50 mg tablet
Number of subjects: 36
Study 10701699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine oral reference solution (50 mg/200 mL)
Number of subjects: 36
Study 10701699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg production‐line tablet
Number of subjects: 36
Study 10701699 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine oral reference solution (200 mg/200 mL)
Number of subjects: 36
Study 8634003 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (cognitive, behavioral, brief psychodynamic, and group therapies)
Number of subjects: 0
Study 8634003 — intervention group
Group type: COMPARATOR
Intervention: Combined psychotherapy-pharmacotherapy regimens
Number of subjects: 0
Study 1773125 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bednets (500 mg/m2)
Number of subjects: 0
Study 1773125 — intervention group
Group type: COMPARATOR
Intervention: Blank formulation (similar to EC without permethrin)
Number of subjects: 0
Study 1773125 — intervention group
Group type: COMPARATOR
Intervention: Lambda-cyhalothrin (25 mg/m2)
Number of subjects: 0
Study 1773125 — intervention group
Group type: COMPARATOR
Intervention: Permethrin (5, 50, or 500 mg/m2)
Number of subjects: 0
Study 1773125 — intervention group
Group type: COMPARATOR
Intervention: Untreated nets
Number of subjects: 0
Study 6764605 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SL-76188
Number of subjects: 10
Study 6764605 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 mg SL-76188
Number of subjects: 10
Study 6764605 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg SL-76188
Number of subjects: 10
Study 6764605 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg D-amphetamine
Number of subjects: 10
Study 6764605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31293146 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation with anticipation using ExoPinch finger robot
Number of subjects: 8
Study 31293146 — intervention group
Group type: COMPARATOR
Intervention: Observation without anticipation
Number of subjects: 8
Study 28382371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 5680
Study 28382371 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 5680
Study 28382371 — intervention group
Group type: COMPARATOR
Intervention: Cangrelor vs Clopidogrel
Number of subjects: 5680
Study 26122743 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery Medical Device (experimental group)
Number of subjects: 22
Study 26122743 — intervention group
Group type: COMPARATOR
Intervention: Traditional 2-mm osteotome (control group)
Number of subjects: 22
Study 23549769 — intervention group
Group type: EXPERIMENTAL
Intervention: Box Trainer
Number of subjects: 28
Study 23549769 — intervention group
Group type: COMPARATOR
Intervention: VR Simulator
Number of subjects: 28
Study 20589515 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg plus diazepam
Number of subjects: 120
Study 20589515 — intervention group
Group type: COMPARATOR
Intervention: placebo plus diazepam
Number of subjects: 120
Study 19451213 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (ET)
Number of subjects: 55
Study 19451213 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (ET)
Number of subjects: 55
Study 15640298 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 10
Number of subjects: 2326
Study 15640298 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 100
Number of subjects: 2326
Study 15640298 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 200
Number of subjects: 2326
Study 15640298 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 400
Number of subjects: 2326
Study 15640298 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects presented as headache
Number of subjects: 2326
Study 15640298 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects presented as constipation
Number of subjects: 2326
Study 15640298 — intervention group
Group type: EXPERIMENTAL
Intervention: Married respondents
Number of subjects: 2326
Study 12879472 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine and carboplatin (GC)
Number of subjects: 372
Study 12879472 — intervention group
Group type: COMPARATOR
Intervention: mitomycin, ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP)
Number of subjects: 372
Study 10386529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) titrated from 100 mg/day over 6 weeks
Number of subjects: 181
Study 10386529 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT) titrated from 200 mg/day
Number of subjects: 181
Study 10386529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 181
Study 10386529 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 181
Study 8885910 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol 2 mg alone
Number of subjects: 62
Study 8885910 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy with norethisterone 1 mg
Number of subjects: 62
Study 1369518 — intervention group
Group type: EXPERIMENTAL
Intervention: Live anesthetized dogs
Number of subjects: 0
Study 1369518 — intervention group
Group type: COMPARATOR
Intervention: Cadavers
Number of subjects: 0
Study 6405877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with spontaneous ventilation
Number of subjects: 55
Study 6405877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia with spontaneous ventilation
Number of subjects: 55
Study 6405877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with controlled ventilation
Number of subjects: 55
Study 6405877 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia with controlled ventilation
Number of subjects: 55
Study 6405877 — intervention group
Group type: COMPARATOR
Intervention: Control group of orthopaedic patients
Number of subjects: 55
Study 31770507 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion protocol implementation
Number of subjects: 1441
Study 31770507 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion protocol compliance
Number of subjects: 1441
Study 31770507 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets transfusion compliance
Number of subjects: 1441
Study 31770507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate transfusion compliance
Number of subjects: 1441
Study 31770507 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood cells transfusion compliance
Number of subjects: 1441
Study 31770507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma transfusion compliance
Number of subjects: 1441
Study 30293188 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber posts
Number of subjects: 38
Study 30293188 — intervention group
Group type: COMPARATOR
Intervention: Titanium posts
Number of subjects: 38
Study 28693520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with palliative care leaders in primary health care centers
Number of subjects: 4640
Study 28693520 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (control)
Number of subjects: 4640
Study 28693520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with palliative care leaders
Number of subjects: 4640
Study 25819484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg/kg)
Number of subjects: 3017
Study 25819484 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3017
Study 23000080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 6 months
Number of subjects: 160
Study 23000080 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet for 6 months
Number of subjects: 160
Study 23000080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aerobic exercise and DASH diet for 6 months
Number of subjects: 160
Study 23000080 — intervention group
Group type: COMPARATOR
Intervention: Health education (control group)
Number of subjects: 160
Study 21784767 — intervention group
Group type: EXPERIMENTAL
Intervention: sPLA(2) activity measurement
Number of subjects: 3708
Study 21784767 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro‐B‐type natriuretic peptide
Number of subjects: 3708
Study 21784767 — intervention group
Group type: EXPERIMENTAL
Intervention: high‐sensitivity cardiac troponin T
Number of subjects: 3708
Study 19412139 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried femoral ring allograft (FD)
Number of subjects: 50
Study 19412139 — intervention group
Group type: COMPARATOR
Intervention: Frozen femoral ring allograft (FZ)
Number of subjects: 50
Study 19412139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 17563217 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 145
Study 17563217 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 145
Study 17563217 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CM and CBT
Number of subjects: 145
Study 17563217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored gay-specific version of CBT
Number of subjects: 145
Study 16364829 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (0.1, 0.2, and 0.3 mg/kg for 1 h)
Number of subjects: 11
Study 12059866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12059866 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 20
Study 12059866 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 20
Study 12059866 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% and Brimonidine 0.2% (concomitant therapy)
Number of subjects: 20
Study 12059866 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol/Brimonidine
Number of subjects: 20
Study 12059866 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine and Timolol/Brimonidine (concomitant treatment)
Number of subjects: 20
Study 10228816 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal psychotherapeutic support in addition to routine care during the hospital stay
Number of subjects: 271
Study 10228816 — intervention group
Group type: COMPARATOR
Intervention: Standard care provided on the surgical wards
Number of subjects: 271
Study 8758126 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad spectrum antibiotics
Number of subjects: 27
Study 8758126 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 27
Study 8758126 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without pulmonary disease)
Number of subjects: 27
Study 1869979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole with low-level treadmill exercise
Number of subjects: 78
Study 1869979 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole infusion alone
Number of subjects: 78
Study 1869979 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole with isometric handgrip
Number of subjects: 78
Study 6139346 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zetidoline
Number of subjects: 10
Study 6139346 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zetidoline
Number of subjects: 10
Study 6139346 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg zetidoline
Number of subjects: 10
Study 6139346 — intervention group
Group type: COMPARATOR
Intervention: 2 mg haloperidol (positive control)
Number of subjects: 10
Study 6139346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30156479 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 665
Study 30156479 — intervention group
Group type: COMPARATOR
Intervention: Best medical care alone
Number of subjects: 665
Study 29737150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® 150 mg/day
Number of subjects: 77
Study 29737150 — intervention group
Group type: EXPERIMENTAL
Intervention: Antispasmina col forte (50 mg papaverine hydrochloride + 10 mg belladonna extract when needed)
Number of subjects: 77
Study 29737150 — intervention group
Group type: COMPARATOR
Intervention: Buscopan (10 mg when needed)
Number of subjects: 77
Study 27207890 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Low-Glucose Suspend (PLGS) system
Number of subjects: 127
Study 23582234 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal glutamine supplementation
Number of subjects: 65
Study 23582234 — intervention group
Group type: COMPARATOR
Intervention: Control (no glutamine supplementation)
Number of subjects: 65
Study 22374556 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-alpha-lipoic acid (ALA) 300, 600, 900, and 1200 mg/day for 6 months
Number of subjects: 38
Study 22374556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22374556 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-alpha-lipoic acid (ALA)
Number of subjects: 38
Study 20131188 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful electrical cardioversion (EC)
Number of subjects: 43
Study 20131188 — intervention group
Group type: COMPARATOR
Intervention: Persistent AF
Number of subjects: 43
Study 16530916 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse supported discharge
Number of subjects: 111
Study 16530916 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 111
Study 17038827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal, inactivated trivalent influenza virus vaccine (7.5, 15, or 30 microg hemagglutinin antigen)
Number of subjects: 64
Study 17038827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal, inactivated trivalent influenza virus vaccine (30 microg hemagglutinin antigen)
Number of subjects: 64
Study 17038827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12180373 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs
Number of subjects: 0
Study 12180373 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 10486372 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) and endoscopy
Number of subjects: 61
Study 10486372 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy alone
Number of subjects: 61
Study 10486372 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment after evaluation with EUS and endoscopy
Number of subjects: 61
Study 7496979 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-zone 6.0-millimeter ablations
Number of subjects: 80
Study 7496979 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-zone ablations
Number of subjects: 80
Study 2127723 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) during the immediate postoperative period (Group I)
Number of subjects: 27
Study 2127723 — intervention group
Group type: COMPARATOR
Intervention: Conventional serum therapy during the immediate postoperative period (Group II)
Number of subjects: 27
Study 2127723 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 27
Study 145840 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride (1 to 4 mg intramuscularly)
Number of subjects: 4
Study 145840 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (2 mg intramuscularly) or Sulpiride (100 mg intramuscularly) pretreatment
Number of subjects: 4
Study 29745434 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized transcutaneous electroacupuncture (STEA)
Number of subjects: 18
Study 29745434 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 18
Study 30650286 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule (NC)
Number of subjects: 180
Study 30650286 — intervention group
Group type: COMPARATOR
Intervention: Conventional hypoglycemic therapy
Number of subjects: 180
Study 25096175 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar decompression
Number of subjects: 106
Study 25096175 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 106
Study 25096175 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 106
Study 25096175 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant fusion
Number of subjects: 106
Study 25096175 — intervention group
Group type: EXPERIMENTAL
Intervention: Spondylolisthesis
Number of subjects: 106
Study 25096175 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal instability
Number of subjects: 106
Study 23200158 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer aggression (PA) class
Number of subjects: 694
Study 23200158 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer aggression + peer victimization (PAPV) class
Number of subjects: 694
Study 23200158 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple domains of violence (MDV) class
Number of subjects: 694
Study 23200158 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PAPV class to MDV class
Number of subjects: 694
Study 19404655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammotome (MT)
Number of subjects: 62
Study 19404655 — intervention group
Group type: COMPARATOR
Intervention: ATEC (A)
Number of subjects: 62
Study 19404655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems (MT and A)
Number of subjects: 62
Study 18472356 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy plus adjuvant chemotherapy (CRT)
Number of subjects: 316
Study 18472356 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 316
Study 15684293 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg
Number of subjects: 24
Study 15684293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14755361 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antidiabetic drugs
Number of subjects: 0
Study 10373049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restricted (SR) diet for 5 days
Number of subjects: 8
Study 10373049 — intervention group
Group type: COMPARATOR
Intervention: Control diet (C) for 5 days
Number of subjects: 8
Study 8706291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patches, 0.05 mg/day
Number of subjects: 0
Study 8706291 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal implants containing 50 mg oestradiol
Number of subjects: 0
Study 8706291 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal implants containing 50 mg oestradiol with 100 mg testosterone
Number of subjects: 0
Study 8706291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 0
Study 8706291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol implants
Number of subjects: 0
Study 8706291 — intervention group
Group type: COMPARATOR
Intervention: Control group (women with ovaries)
Number of subjects: 0
Study 1647495 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 639
Study 1647495 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg sumatriptan
Number of subjects: 639
Study 1647495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study 1647495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg or 8 mg)
Number of subjects: 639
Study 6849778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 5
Study 6849778 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 5
Study 6849778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31242976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (Arm A) - 100 mg/m² 3-weekly or 40 mg/m² weekly during radiation
Number of subjects: 40
Study 31242976 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (Arm B) - loading dose 400 mg/m² one week before radiation followed by 250 mg/m² weekly during radiation
Number of subjects: 40
Study 29851894 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving a Section 8 housing voucher
Number of subjects: 0
Study 27422360 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal suture ligation (IL)
Number of subjects: 28